Colorectal Cancer Molecular Diagnostics Market Report Provides Insights Into Market Evolution And Growth Prospects

The colorectal cancer molecular diagnostics market is on the cusp of significant expansion, driven by advancements in technology and a growing emphasis on precision medicine. As diagnostic tools evolve to become more effective and less invasive, this sector is seeing increased attention from healthcare providers and investors alike. Here is a detailed analysis of the market size, key players, emerging trends, and segmentation.

Forecasted Market Size and Growth Trajectory of the Colorectal Cancer Molecular Diagnostics Market
The colorectal cancer molecular diagnostics market is projected to experience robust growth, reaching a value of $4.15 billion by 2030. This growth corresponds to a compound annual growth rate (CAGR) of 8.3% during the forecast period. The expansion is primarily fueled by increased investments in precision oncology, a rising demand for minimally invasive diagnostic methods, the broadening scope of genomic testing programs, the growing integration of artificial intelligence in cancer diagnostics, and heightened attention on monitoring treatment responses. Important trends shaping this market include the wider adoption of molecular biomarker testing, the growing use of PCR and sequencing technologies, an increased demand for personalized oncology diagnostics, the development of companion diagnostics, and a strong focus on early detection of cancer.

The colorectal cancer molecular diagnostics market size has grown strongly in recent years. It will grow from $2.78 billion in 2025 to $3.02 billion in 2026 at a compound annual growth rate (CAGR) of 8.5%. The growth in the historic period can be attributed to increasing colorectal cancer incidence rates, expansion of diagnostic laboratory infrastructure, rising adoption of molecular testing protocols, improved awareness of early screening, growing use of precision medicine approaches.

Download a free sample of the colorectal cancer molecular diagnostics market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13120&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Key Companies Leading the Colorectal Cancer Molecular Diagnostics Market
Several global corporations are at the forefront of the colorectal cancer molecular diagnostics market. Notable players include Johnson & Johnson, Bayer AG, Abbott Laboratories, Danaher Corporation, Becton dic*kinson and Company, Biocartis Group NV, Agilent Technologies Inc., Grifols S.A., Hologic Inc., Biomérieux SA, Quidel Corporation, Bio-Rad Laboratories Inc., Qiagen N.V., Exact Sciences Corporation, Illumina Inc., Cepheid, Myriad Genetics Inc., Guardant Health, Luminex Corporation, GenMark Diagnostics, Amoy Diagnostics Co. Ltd., MDxHealth Inc., HTG Molecular Diagnostics Inc., GenPath Diagnostics, and geneOmbio Technologies Pvt.

A significant event in this market took place in July 2023 when New Day Diagnostics LLC, a US-based medical equipment manufacturer, acquired the assets of Epigenomics AG. This acquisition, for an undisclosed sum, expanded New Day Diagnostics' cancer diagnostics portfolio by obtaining intellectual property related to Epi ProColon, a screening technology designed for the non-invasive detection of colorectal cancer. Epigenomics AG, based in Germany, specializes in colorectal cancer molecular diagnostics.

View the full colorectal cancer molecular diagnostics market report:
https://www.thebusinessresearchcompany.com/report/colorectal-cancer-molecular-diagnostics-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Emerging Trends Boosting the Colorectal Cancer Molecular Diagnostics Market
Leading companies in this field are increasingly focusing on developing blood-based liquid biopsy tests that offer non-invasive, early cancer detection. These tests improve patient compliance compared to traditional colonoscopy methods and support broader population screening as reimbursement policies and screening guidelines evolve. Liquid biopsy involves analyzing tumor-derived biomarkers from a blood sample, providing molecular-level sensitivity and the ability to screen asymptomatic individuals.

For example, in July 2024, Guardant Health, a US-based precision oncology firm, introduced Shield-a blood-based colorectal cancer screening test approved by the U.S. Food and Drug Administration for average-risk adults aged 45 and older. Shield is a multi-marker assay that detects circulating tumor signals, developed through the extensive ECLIPSE clinical program. It demonstrated sufficient sensitivity and specificity to earn FDA approval as a primary screening tool. The test uses sequencing combined with proprietary bioinformatics to identify methylation and other tumor-related signals in plasma. Its key advantages include a simple single blood draw, potential for higher screening participation, pathways to Medicare coverage, and its use in population screening and as a preliminary step to diagnostic colonoscopy for positive cases-enabling earlier detection with fewer invasive procedures.

How the Colorectal Cancer Molecular Diagnostics Market Is Structured
The colorectal cancer molecular diagnostics market is categorized as follows:

1) By Type:
- Instruments
- Reagents and Kits
- Services

2) By Technology:
- Polymerase Chain Reaction (PCR)
- Sequencing
- Mass Spectrometry
- Transcription Mediated Amplification
- Chips and Microarrays
- Isothermal Nucleic Acid Amplification Technology (INAAT)

3) By End Users:
- Hospitals
- Ambulatory Surgical Centers
- Diagnostic Laboratories
- Homecare Settings

Further breakdown includes:
- Instruments such as PCR machines, sequencers, and microarrays
- Reagents and kits including DNA or RNA extraction kits, assay kits, and reagent packs
- Services covering diagnostic testing, genetic testing, and consultation

This segmentation offers a comprehensive view of the market landscape, allowing stakeholders to identify key growth areas and tailor their strategies accordingly.

New strategic additions in our 2026 market reports include market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, along with updated graphics and tables.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.